Doctors: FDA warning about Novo's diabetes pill will not influence sales
The requirement of the American health authorities for Novo Nordisk to print warnings on the patient information sheet of their new diabetes pills will not cause patients to reject the treatment, according to Danish doctors. “I think most doctors will be relaxed about it,” says the Chairman of the association of Danish Endocrinologists.
Novo Nordisk’s new diabetes pill Rybelsus can raise the risk of several serious illnesses. It may therefore never be used by certain patient groups and is not recommended as a first choice of treatment.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
